Description

NOBIVAC® Canine Edge 1-DAPPvL4 has been shown to be effective for vaccination of healthy dogs 8 weeks of age or older against canine distemper virus, canine adenovirus type 1 (hepatitis), canine parainfluenza virus, canine parvovirus, L. grippotyphosa, L. pomona, L. icterohaemorrhagiae, and L. canicola. Also effective against mortality and leptospiruria (shedding of Leptospira in the urine) caused by L. canicola, L. icterohaemorrhagiae, L. pomona and L. grippotyphosa.

Benefits

Safety confirmed in 749-dog field study
Proven safe across a variety of dog breeds and ages
Featuring an even higher level of quality due to VacciPure™ filtration

Dosage and Administration

Shake the Nobivac^® Lepto₄ vial and transfer its contents to the Nobivac^® Canine 1-DAPPv vial aseptically. Mix gently until dissolved. Use entire contents immediately after rehydration.

Inject one dose (1 mL) subcutaneously. The initial dose may be given at 8 weeks of age or older. Repeat at 2 to 4 week intervals until the dog is 12 weeks of age. A minimum of two doses is required for primary immunization. 

WARNINGS:

• Contains gentamicin and amphotericin B as preservatives.
• Vaccinate only healthy, non-parasitized dogs.
• Do not vaccinate pregnant bitches.
• The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions. Antidote: Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction.
• The age at which maternal antibody for canine parvovirus no longer interferes with the development of active immunity varies according to the bitch’s titer and quantity of colostral antibodies absorbed by the puppy.


Nobivac Canine Edge 1-DAPPv+L4 is a registered trademark of Intervet Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co. Inc.

Click here for our Vaccine Shipping Schedule.